Cretostimogene

PIVOT 006 Lowers Bladder Tumor Recurrence

CG Oncology reported a Phase 3 recurrence-free-survival hazard ratio of 0.32 for adjuvant intravesical cretostimogene versus surveillance after complete tumor resection in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer. It remains investigational; full results…